Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Jonas Salk artists have joined the scientists to achieve an understanding of man in all his physical, mental and spiritual complexity. Such interchanges might lead, he would hope, to a new and important school of thinkers he would designate as biophilosophers." Salk told his cousin, Joel Kassiday, at a meeting of the Congressional Clearinghouse on the Future on Capitol Hill in 1984 that he was optimistic that ways to prevent most human and animal diseases would eventually be developed. Salk said people must be prepared to take prudent risks, since "a risk-free society would become a dead-end society" without progress. Salk describes